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ABSTRACT
Background    In hepatic resection for liver tumors, re-
ducing operation time and blood loss are important for 
postsurgical complication prevention. This study aimed 
to compare the safety and efficacy of the LigaSure Small 
Jaw (Covidien, Boulder, CO) with those of the Cavitation 
Ultrasonic Surgical Aspirator (CUSA) system (Integra 
Life Sciences, Plainsboro, NJ) in hepatic surgery. 
Methods    We enrolled 102 patients with liver tumors, 
of whom 51 underwent liver resection with the CUSA 
(CUSA group) between March 2004 and April 2011. 
Another 51 underwent resection with the LigaSure 
Small Jaw (LS group) between June 2011 and July 2012. 
We stratified patients by time period depending on the 
instrument used, and compared operative duration; in-
traoperative bleeding; and postoperative liver function 
and complication rate.
Results    Total operation time (mean ± SD) was sig-
nificantly shorter in the LS group than in the CUSA 
group (358.8 ± 91.7 versus 460.6 ± 146.1 min, P < 0.001). 
Blood loss was not significantly different between the 2 
groups. Frequency of postoperative complications was 
lower, but not significantly, in the LS group. 
Conclusion    The LigaSure Small Jaw may allow a 
shorter total operative duration than the CUSA device. 
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In recent years, vessel-sealing systems have been 
developed and used widely in the fields of urologic, 
gynecologic, and gastrointestinal surgery.1–5 Our de-
partment previously used the Cavitation Ultrasonic 
Surgical Aspirator (CUSA) (Integra Life Sciences, 
Plainsboro, NJ) for liver resection. Under this system, 
liver resection generally comprises two separate pro-
cedures: First, crushing of the liver parenchyma and 
subsequent aspiration of the crushed tissue and blood 
to expose the intrahepatic vessels; and second, ligation 
or sealing of the exposed vessels, which is typically 
achieved by manual ligation, clips, or electrocautery.
 The use of LigaSure instruments confers several 
advantages, including sealing of the intrahepatic vessel 
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without foreign bodies such as clips, a smaller number of 
ties required to complete the procedure, and the ability 
to close vessels that are of larger diameter, up to 7 mm, 
than those that can be closed by electrocautery. These 
procedures are all performed using a single instrument.
 In February of 2011, the LigaSure Small Jaw 
(Covidien, Boulder, CO) (Fig. 1) was introduced as the 
newest instrument in the LigaSure family of advanced 
surgical vessel-sealing devices with a cutting blade. The 
instrument is a manual device 18.8 cm in length that is 
designed to be used in confined surgical spaces where 
access and visibility are limited. This instrument is de-
signed for open surgery, offers the ability selectively to 
cut or grasp tissue and permanently seal vessels up to 
and including those 7 mm in diameter, lymphatic vessels 
and tissue bundles without sutures, staples or clips.
 We considered the features of this instrument to re-
semble those of a Pean clamp, which is used to perform 
crimping and crushing. Although the LigaSure Small 
Jaw is somewhat wider than a Pean clamp, the device 
can be effectively used to crush liver parenchyma. More 
importantly, liver resection is known to have a relatively 
high risk of intraoperative hemorrhage; therefore, bleed-
ing must be strictly controlled.
 Studies evaluating the advantages of LigaSure 
instruments compared with the conventional clump 
crushing method have demonstrated reduced blood loss 
during liver resection;6–8 however, LigaSure Small Jaw 
has not yet been evaluated with respect to a reduction 
in blood loss in liver resection. LigaSure Small Jaw is 
a smaller size than conventional LigaSure instruments, 
and it is easy to handle and manage, similar to the con-
ventional clump crashing method. We expected that the 
device would reduce the amount of bleeding in lapa-
rotomy for liver resection.
 We have found the LigaSure instrument to confer 
distinct advantages, including control of bleeding, crush-
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Fig. 1. LigaSure Small Jaw (Covidien; Boulder, CO). Left: whole image of the vessel (18.8 cm in length). Right: enlarged 
image of the vessel head when the vessel is in an opened state, viewed from the bottom of the vessel head.
ing ability similar to that of a Pean clamp, and the abil-
ity to seal and cut almost simultaneously during liver 
transection. We therefore switched from the CUSA to 
the LigaSure Small Jaw in June of 2011. The goal of 
this study was to compare the safety and efficacy of the 
LigaSure Small Jaw vessel-sealing system with those of 
the CUSA in liver resection.
 
MATERIALS AND METHODS
This was a retrospective study of 225 patients who 
underwent hepatic resection at our institution between 
March 2004 and July 2012. Patients were assigned to 
groups treated with liver resection with the CUSA de-
vice (CUSA group, n = 51) from March 2004 to April 
2011, or the new LigaSure Small Jaw vessel-sealing 
system (LS group, n = 51) from June 2011 to July 2012. 
Between March 2004 and April 2011, we performed all 
operations using the CUSA. Patients were consecutively 
selected during the trial period, but excluded if they had 
undergone laparoscopic liver resection, or were missing 
data related to pre- or post-operative liver function. This 
resulted in 102 patients being chosen to be analyzed in 
this study. The difference in the recruitment period for 
the CUSA and LS groups is a result of the increase in 
operations for liver cancer in recent years; our institution 
had more patients in the latter period compared with 
those in the former period.
Surgical technique
Two surgeons (K. E. and Y. H.) alternately performed all 
operations in this study. No patient was specifically as-
signed to either doctor. Liver transection was achieved 
using primarily either the CUSA or LigaSure Small Jaw. 
In both groups, water-cooled bipolar forceps and the VIO 
BiClamp (ERBE GmbH, Tübingen, Germany) were used 
in combination. The Pringle maneuver was performed 
intermittently with 15 min of clamping and 5 min of un-
clamping, patients were excluded if the intestinal adhesion 
proximal to the hepatoduodenal ligament was severe.
 In the CUSA group, liver parenchyma was crushed 
using the CUSA device and exposed vessels were suc-
cessively manually ligated or clipped, then sealed and 
cut. In contrast, the LigaSure Small Jaw was used to 
crush liver parenchyma similarly to using a Pean clamp, 
seal residual vessels up to about 7 mm in diameter 
and complete dissection throughout the procedure. All 
procedures, such as abdominal section, detaching and 
unfolding liver, washing surgical field, indwelling drain 
tube and abdominal closure, were similarly performed 
throughout the operations between the 2 groups.
Surgical outcomes
Surgical outcomes included operative duration, intraoper-
ative blood loss and postoperative variables. Postoperative 
variables were liver function and complications. Postoper-
ative liver function was assessed by measuring laboratory 
data on postoperative days 1, 3, 5 and 7. Of these data, the 
maximum transaminase value, maximum bilirubin value 
and minimum albumin value were used for analysis. 
 
Statistical analysis 
Quantitative variables were compared using analysis of 
variance. Comparisons between groups were performed 
using the chi-square test and Student’s t-test. All data are 
expressed as the mean ± SD. P < 0.05 was considered to 
represent statistical significance.
RESULTS
Characteristics of the 102 patients are presented in 
Table 1. The LS group was older than the CUSA group 
(P < 0.05). No statistically significant differences were 
found between the 2 groups for clinical features, in-
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Table 2. Operative duration
  CUSA group LS group P
 Operative duration [range], min 460.6 ± 146.1 [160–803] 358.8 ± 91.7 [177–630] < 0.0001
Non-cancerous region
     Non-cirrhosis (nl/ch) 442.7 ± 1498.8 350.9 ± 95.3 < 0.005
     Cirrhosis (lc) 518.8 ± 121.2  401.0 ± 56.3 < 0.05
 Data, mean ± SD.
ch, chronic hepatitis; CUSA group, group treated with the Cavitation Ultrasonic Surgical Aspirator system; lc, liver cirrhosis; LS group, 
group treated with the LigaSure Small Jaw system; nl, normal liver.
Statistics: Student’s t-test.
Table 1. Background characteristics
  CUSA group LS group P
 Number of patients 51 51
Duration of use Mar. 2004–Apr. 2011 Jun. 2011–Jul. 2012
Sex (male/female ratio) 38/13 43/8 0.3273†
Age, mean ± SD [range], yr 63.9 ± 11.2 [40–81] 68.9 ± 9.9 [46–85] < 0.05†† 
Background liver
     Hepatitis B 19 (37.2%) 23 (45.1%) 0.2911†
     Hepatitis C 17 (33.3%) 10 (19.6%)
     Others 15 (29.4%) 18 (35.3%)
Cause of disease
     Hepatocellular carcinoma 33 (64.7%) 33 (64.7%) 0.9286†
     Metastatic liver tumor 13 (25.5%) 14 (27.5%)
     Cholangiocarcinoma   5 (9.8%)   4 (7.8%)
Pathological findings of non-cancerous region
     Normal liver (nl) 13 (25.5%) 11 (21.6%) 0.3301†
     Chronic hepatitis (ch) 26 (51.0%) 32 (62.9%)
     Liver cirrhosis (lc) 12 (23.5%)   8 (15.7%)
Preoperative liver function, mean ± SD
     Total bilirubin, mg/dL 0.73 ± 0.27 0.74 ± 0.26 0.9412††
     Aspartate aminotransferase, U/L 40.1 ± 49.9 36.8 ± 21.6 0.6607††
     Alanine aminotransferase, U/L 36.3 ± 28.8 32.7 ± 23.2 0.4177†† 
     Albumin, g/dL   3.97 ± 0.44   4.01 ± 0.40 0.2165††
     Indocyanine green retention, % 12.6 ± 5.9 13.8 ± 6.1 0.3754††
Type of hepatectomy
     Partial hepatectomy 14 (27.5%)   9 (17.6%) 0.2391†
     Subsegmentectomy   8 (15.7%)   4 (7.8%)
     One hepatic segmentectomy 11 (21.6%) 18 (35.3%)
     Two hepatic segmentectomy or over 18 (35.3%) 20 (39.2%) 
 CUSA group, group treated with the Cavitation Ultrasonic Surgical Aspirator system; LS group, group treated with the LigaSure Small 
Jaw system.
Statistics: †chi-square test; ††Student’s t-test.
cluding condition of the livers (cirrhotic versus non-
cirrhotic), cause of disease, pathological findings of non-
cancerous regions and preoperative liver function; or for 
type of hepatectomy.
 Operative duration is shown in Table 2 and total 
blood loss is shown in Table 3. The entire operative du-
ration was 460.6 ± 146.1 min (range, 160–803 min) for 
the CUSA group and 358.8 ± 91.7 min (range, 177–630 
min) for the LS group. Total operative duration was sig-
nificantly shorter in the LS group for both non-cirrhotic 
(P < 0.005) and cirrhotic (P < 0.05) livers. 
 There was less intraoperative blood loss in the LS 
group (681.7 ± 543.7 mL; range, 34–2,500 mL) than in 
the CUSA group (894.0 ± 856.2 mL; range, 20–3,710 
mL) but the difference was not statistically significant. 
 Postoperative liver function parameters for each 
group are listed in Table 4. Among these outcomes, 
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were much higher after procedures 
using the LigaSure Small Jaw than in those using the 
CUSA. Postoperative total bilirubin and albumin were 
not statistically different between the 2 groups. 
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 Postoperative complications occurred in 18 pa-
tients in the CUSA group and in 11 patients in the 
LS group (Table 5). Eight patients (13.9%) in CUSA 
group and 2 patients (5.6%) in LS group experienced 
bile leakage, with a difference that was not significant. 
Other complications, including bile duct stenosis, pleu-
ral fluid, wound infection, intraperitoneal abscess and 




A randomized clinical trial comparing ultrasonic with 
manual clamp transection of the liver showed no differ-
ence in blood loss or operation time.9 In our practice, 
exposure of vessels and bile ducts using the CUSA 
required a great deal of time, whereas the LigaSure 
Small Jaw made it possible to expose residual vessels by 
Table 4. Postoperative liver function
 CUSA group LS group P
Total bilirubin, mg/dL     1.82 ± 1.14     1.91 ± 1.17 0.4329
Aspartate aminotransferase, U/L 442.5 ± 259.6 683.7 ± 500.6 < 0.005
Alanine aminotransferase, U/L 356.6 ± 253.1 599.9 ± 439.0 < 0.001
Albumin, g/dL     2.75 ± 0.34     2.66 ± 0.35 0.1726
Data, mean ± SD.
CUSA group, group treated with the Cavitation Ultrasonic Surgical Aspirator system; LS group, group treated with the LigaSure Small 
Jaw system.
Statistics: Student’s t-test.
Table 5. Postoperative complications
 CUSA group LS group Total P
Bile leakage 8 (15.7%) 2 (3.9%) 10 (9.8%) 0.0539
Bile duct stenosis  0 (0.0%) 1 (2.0%)   1 (1.0%) > 0.9999
Pleural fluid 3 (5.9%) 4 (7.8%)   7 (6.9%) > 0.9999
Wound infection 4 (7.8%) 2 (3.9%)   6 (5.9%) 0.6779
Intraperitoneal abscess 3 (5.9%) 1 (2.0%)   4 (3.9%) 0.6175
Pneumonia 0 (0.0%) 1 (2.0%)   1 (1.0%) > 0.9999 
CUSA group, group treated with the Cavitation Ultrasonic Surgical Aspirator system; LS group, group treated with the LigaSure Small 
Jaw system.
Statistics: Student’s t-test.
crushing, then sealing and cutting a vessel using a single 
device, which greatly reduced performance time. For 
safety, the most challenging exposures of major hepatic 
veins and Glisson’s capsule were performed using a 
Pean clamp. 
 This study shows that the LigaSure Small Jaw can 
be safely used during liver parenchymal resection and 
significantly reduces the operation time for liver resec-
tion compared with the CUSA device. This result rep-
resents an operative duration approximately 100 min 
shorter for the LS group than for the CUSA group (P < 
0.0001). Shortening the operation time in liver resection 
has been demonstrated in previous studies using con-
ventional LigaSure,6 but not yet with the newest device, 
LigaSure Small Jaw. Time reduction was also observed 
for resection of cirrhotic livers, which are difficult to 
sever by the crush-clamp technique using a Pean clamp 
Table 3. Intraoperative blood loss
  CUSA group LS group P
 Intraoperative blood loss [range], mL   894.0 ± 856.2 [20–3710] 681.7 ± 543.7 [34–2500] 0.1641
Non-cancerous region
     Non-cirrhosis (nl/ch)   817.3 ± 822.7 672.2 ± 552.2 0.3733
     Cirrhosis (lc) 1143.3 ± 951.5 733.1 ± 527.7 0.3459
 Data, mean ± SD.
ch, chronic hepatitis; CUSA group, group treated with the Cavitation Ultrasonic Surgical Aspirator system; lc, liver cirrhosis; LS group, 
group treated with the LigaSure Small Jaw system; nl, normal liver.
Statistics: Student’s t-test.
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and often difficult to achieve hemostasis. An advantage 
of using the LigaSure is that sealing of blood vessels 
does not require direct exposure, which can increase op-
erative time and cause unnecessary bleeding.
 Previous studies have demonstrated that using 
LigaSure instruments reduced the amount of blood loss 
in liver resection compared with conventional clump 
crash methods.6–8, 10 However, Dokelstic et al. compared 
3 instruments, the clamp crushing method, CUSA and 
LigaSure in liver resection, and found no difference in 
the intraoperative blood loss between the groups.11 
 A study comparing the LigaSure Small Jaw with 
conventional suture ligation in thyroidectomy showed 
intraoperative blood loss to be statistically significantly 
less for the LigaSure Small Jaw.12 Although this single 
study showed a reduction in blood loss by the LigaSure 
Small Jaw in thyroidectomy, this device had not yet been 
evaluated in liver resection. 
 Our results showed that total blood loss in patients 
with non-cirrhotic liver in the LS group was approxi-
mately 20% less than in the CUSA group, and in pa-
tients with cirrhotic liver, blood loss in the LS group was 
also 20% less than in the CUSA group. However, these 
data were not significantly different. LigaSure’s advan-
tage over CUSA with respect to mitigating bleeding has 
not yet been demonstrated.
 Postoperative transaminase was considerably higher 
in the LS group than in the CUSA group. In one study, 
LigaSure diathermy was shown to be associated with 
significantly higher transaminase levels than convention-
al techniques.7 According to those authors, the scalded 
liver parenchyma on the cut surface may have explained 
this increase, as the maximum AST value was signifi-
cantly correlated with the resection time and area. Fol-
low-up computed tomography revealed the burned area 
on the cut surface on the liver. In that study, the levels of 
AST and ALT were not significantly different on post-
operative day 5 between the 2 groups, and were nearly 
the same level on postoperative day 7. In this study, we 
also demonstrated that the level of these enzymes were 
similar on postoperative day 5 between the 2 groups 
(date not shown). An explanation for this may be that the 
damage to scalded liver parenchyma resolved over time 
and transaminases reverted to normal levels. 
 In a study examining and comparing 4 sealing de-
vices, including LigaSure instruments, the degree of 
lateral thermal spread of the LigaSure instruments was 
55.5 ˚C, 2 mm away from the cut surface.13 This sup-
ports the hypothesis that tissue was burned by thermal 
spread with the devices, which caused increased postop-
erative transaminase levels.
 Among postoperative complications, an increased 
risk of bile leakage had been identified as a possible 
defect of the vessel-sealing system,14, 15 whereas several 
studies have shown a decreased rate of this complication 
in the LigaSure instrument groups.6, 16, 17 Comparison 
of postoperative bile leakage between LigaSure and 
conventional-method groups was reported in 3 ran-
domized controlled trials6, 11, 18 and 3 non-randomized 
studies.8, 16, 19 The overall risk of bile leakage was 63% 
lower in the LigaSure groups than in the conventional-
method groups (odds ratio 0.37; 95% confidence interval 
0.17–0.78; n = 559). This outcome supports the theory 
that an advantage of the LigaSure is its ability to seal 
both biliary and vascular structures. Our results confirm 
this, showing a low incidence of bile leakage associated 
with the use of the vessel-sealing system. Our results did 
not statistically demonstrate the efficacy in reducing bile 
leakage in the LS group, which was presumably because 
the number of occurrences was too small for compari-
son; however, our results do suggest the LigaSure Small 
Jaw can potentially reduce the incidence of bile leakage.
 The LigaSure Small Jaw Instrument was superior 
to the CUSA in terms of shortening operative time. It 
was also better at reducing intraoperative hemorrhage 
and postoperative complications, but these effects did 
not reach clinically significant levels. Overall, using 
LigaSure Small Jaw Instrument can be advantageous in 
liver resection.
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